Discover 212 paid clinical trials in Boise, Idaho. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 212
Active & Responsive
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
for
Degenerative Disc Disease
Location: San Diego CA, Post Falls ID, Salt Lake City UT,
Sponsor: DiscGenics, Inc.
Sex: All
Age: 18 - 70+
Code: NCT07254806
Phase3, Recruiting
Active & Responsive
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
for
Obesity or Overweight
Location: Meridian ID, Missoula MT, Redmond WA, Las Vegas NV,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07575399
Phase3, Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Boise ID, Meridian ID, Nampa ID, Caldwell ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06058377
Phase3, Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
for
Fallopian Tube Endometrioid Adenocarcinoma,
Location: Boise ID, Meridian ID, Nampa ID, Caldwell ID,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06580314
Phase3, Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
for
Viral Lung Infection and Acute Respiratory Failure
Location: Boise ID, Salt Lake City UT, Fresno CA, Calgary,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT05624450
Phase3, Recruiting
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
for
Cystic Fibrosis
Location: Boise ID, Spokane WA, Salt Lake City UT, Portland OR,
Sponsor: Nicole Hamblett
Sex: All
Age: 12+
Code: NCT06504589
Recruiting
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
for
Myelodysplastic Syndrome
Location: Boise ID, Meridian ID, Nampa ID, Fruitland ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06577441
Phase2, Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
for
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8,
Location: Boise ID, Meridian ID, Nampa ID, Fruitland ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06498635
Phase3, Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
for
Stage I Mixed Cell Type Kidney Wilms Tumor,
Location: Boise ID, Spokane WA, Salt Lake City UT, Portland OR,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 30
Code: NCT06401330
Phase3, Recruiting
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma